Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Frontiers | Systematic Review of Safety and Efficacy of Atacicept in ...
Randomized Phase II JANUS Study of Atacicept in Patients With IgA ...
Atacicept in IgA Nephropathy: Analysis of the Interim Phase 3 Data in ...
Atacicept • Vera Therapeutics
Inside the ORIGIN study: Visual and video abstracts on atacicept for ...
ORIGIN 3 Clinical Trial Evaluating Atacicept in Adults With IgA ...
Frontiers | Kinetics of free and ligand-bound atacicept in human serum
Population pharmacokinetics of atacicept in systemic lupus ...
Atacicept – Application in Therapy and Current Clinical Research
(PDF) Safety and clinical activity of atacicept in the long-term ...
(PDF) Atacicept in multiple sclerosis (ATAMS): a randomised, placebo ...
Belimumab differs from atacicept in that it does not inhibit BAFF ...
Study on the Effects of Atacicept in Adults with IgA Nephropathy
Atacicept in multiple sclerosis (ATAMS): a randomised, placebo ...
Kidney Week 2025: ORIGIN 3 Sets the Stage for Atacicept in IgA ...
Atacicept (TACI-Ig) | B Cell Stimulator | MedChemExpress
Phase 2b and Phase 3 ORIGIN Trials of Atacicept in IgAN | HCPLive
Atacicept in IgAN - Vera Therapeutics
Vera Therapeutics' Atacicept Shows Promising Results in Phase 2b ORIGIN ...
Atacicept Shot Significantly Reduces Proteinuria in IgA Nephropathy: NEJM
Atacicept for IgA nephropathy succeeds in phase III trial ...
Phase 3 ORIGIN Sets Stage for Atacicept in IgA Nephropathy, with ...
(PDF) Efficacy and Safety of Atacicept in Patients with Systemic Lupus ...
(PDF) Atacicept in combination with MMF and corticosteroids in lupus ...
(PDF) Systematic Review of Safety and Efficacy of Atacicept in Treating ...
Atacicept Phase 3 Trial Shows 46% Kidney Disease Improvement in IgA ...
(PDF) Population pharmacokinetics of atacicept in systemic lupus ...
Atacicept in patients with rheumatoid arthritis: Results of a ...
S7A:4 Reduction of systemic lupus flares by atacicept in a randomised ...
A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy | NEJM ...
Efficacy and safety of atacicept for prevention of flares in patients ...
Effect of Atacicept on Renal Function in Patients with Systemic Lupus ...
A) The change in median free atacicept concentration during disease ...
Atacicept Cuts Proteinuria in IgA Nephropathy — How Emerging B‑cell and ...
Antimyeloma response of atacicept in myeloma-osteoclast cocultures. (a ...
Safety and Efficacy of Atacicept in Combination With Rituximab for ...
Atacicept prevents B cell repopulation but not isotype switching or ...
8 Efficacy and safety of atacicept in patients with systemic lupus ...
atacicept | PDF | Medical Specialties | Clinical Medicine
(PDF) Phase I Clinical Study of Atacicept in Patients with Relapsed and ...
Efficacy and Safety of Atacicept in Patients with Systemic Lupus ...
(PDF) Commentary: Systematic Review of Safety and Efficacy of Atacicept ...
Attacking the Origin of IgAN: ORIGIN3 and Atacicept — NephJC
Atacicept Achieves Endpoints in Phase 3 ORIGIN Trial for IgA Nephropathy
Atacicept and the Promise of Targeted Approaches to IgAN | Docwire News
Vera Builds ‘Compelling Profile’ for Atacicept in IgAN, Eyes Q4 Filing ...
Atacicept in patients with rheumatoid arthritis and an inadequate ...
Multimers of atacicept bind to proteoglycans. (a) Size exclusion ...
OP0119 Pharmacodynamic Effects of Atacicept in SLE Patients: 52-Week ...
Atacicept: targeting B cells in multiple sclerosis - PMC
A phase 2b, randomized, double-blind, placebo-controlled, clinical ...
WCN24-1414 ORIGIN 3: PIVOTAL PHASE 3 STUDY EVALUATING EFFECT OF ...
10亿美元分子：Vera大涨49%，Atacicept治疗IgA肾病2b期临床成功 Armstrong 2023年1月25日， Vera ...
Atacicept: Uses, Dosage, Side Effects, Food Interaction & FAQ
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase ...
Vera Therapeutics Announces Positive Week 36 Efficacy and Safety ...
Vera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN ...
Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b ...
Frontiers | Commentary: Systematic Review of Safety and Efficacy of ...
WCN25-2470 Long-term Results from the ORIGIN Phase 2b Study of ...
Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid ...
Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist That Modulates B ...
Science • Vera Therapeutics
(PDF) Atacicept: Targeting B cells in multiple sclerosis
(PDF) Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ...
阿塞西普(Atacicept) - 药物靶点：APRIL x BAFF_在研适应症：免疫球蛋白a肾病，肾小球疾病，肾病综合征_专利_临床_研发
Vera Therapeutics Reports Positive Phase 3 ORIGIN Trial Results for ...
Vera Therapeutics: Waiting For A Pullback (NASDAQ:VERA) | Seeking Alpha
Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept ...
(PDF) CNS Autoimmune Responses in BCMA-Deficient Mice Provide Insight ...
Vera Therapeutics: Stock Rises As IgAN Approval Chances Increase - I'm ...
An Exploratory Dose-Escalating Study Investigating the Safety ...
